RxDoctor Payments Data

Yvonne McLemore

Family · Glendale, AZNPI 1548647936

Payments from drug & device makers

$988in general payments, 2019–2025

Across 17 payments — averaging $58.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$535
  • Averitas Pharma Inc.$122
  • AstraZeneca$119
  • Vertos Medical, Inc.$60
  • Nalu Medical, Inc.$59
  • Abbott$50
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 65th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$114,272
Medicare patients
533
Services billed
1,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine264$47,567
Xtampza ErOxycodone Myristate62$32,587
BelbucaBuprenorphine Hcl47$29,645
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen551$18,280
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen628$17,726
MovantikNaloxegol Oxalate16$11,384
Gabapentin669$9,303
LinzessLinaclotide11$8,664
Oxycodone Hcl526$8,570
Morphine Sulfate ErMorphine Sulfate305$6,449
Pregabalin259$5,717
Lidocaine55$5,290
ButransBuprenorphine16$4,939
Tramadol Hcl326$4,508
OxycontinOxycodone Hcl13$3,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$24$62,233109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,119 family providers in Arizona.

Other family in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →